Evidence map›Paper›PMID 41716337›Full record

ArticleMaterials today. Bio2026

Guanghao Lv, Lei Lei, Jingli Wang, Ying Yang, Yunxiao Zou, Siqi Xie, Ling Wang, Xiaoying Liu, Chenhao Li, Haiqi Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Guanghao LvNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Lei LeiNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Jingli WangNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Ying YangNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Yunxiao ZouNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Siqi XieNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Ling WangNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Xiaoying LiuNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Chenhao LiNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Haiqi WangNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Xingyi LiNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.
Jiaqing WangNational Engineering Research Center of Ophthalmology and Optometry, Zhejiang Key Laboratory of Ophthalmic Drug Discovery and Medical Device Research, Eye Hospital, Wenzhou Medical University, 270 Xueyuan Road, Wenzhou, 325027, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rebamipide is effective for dry eye management, but its insolubility limits formulation development. An optimal design is crucial for patient comfort and maximizing bioavailability. Here we covalently conjugate rebamipide with a peptide motif (FFFYpEH) to generate a peptide-drug conjugate that dramatically improves solubility and enables

Indexed as

Dry eyeEye dropsMucinOcular drug deliveryRebamipide

Identifiers

PMID41716337
PMCPMC12914690

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.